FTN Equity Downgrades Hi-Tech Pharmacal (HITK) from Buy
More News related to HITK
- Hi-Tech Pharmacal's ECR Subsidiary Signs Exclusive Agreement to Commercialize Sleep Aid in Oral Spray Form
- Semi-Annual Changes to the NASDAQ Biotechnology Index
- Hi-Tech Pharmacal to Present at the 20th Annual Oppenheimer Healthcare Conference
- FTN Equity Downgrades Hi-Tech Pharmacal (HITK) from Buy
- Unusual 11 Mid-Day Movers 9/9: ENCO, VVUS, CLZR, HITK, DPTR Higher; OPXA, LRN, ROSG, ELOS Lower
More News related to Downgrades
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
FTN Equity downgrades Hi-Tech Pharmacal (Nasdaq: HITK) to Neutral from Buy.
To see more analyst ratings on HITK Click Here.
Hi-Tech Pharmacal Co., Inc. develops, manufactures, markets, and sells generic, prescription, over-the-counter (OTC), and nutritional products in liquid and semisolid dosage forms in the United States.
Related Categories
DowngradesStocks Mentioned
-0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
